Adaptive Biotechnologies Corporation
Financials
Valuation Metrics
Adaptive Biotechnologies Corporation's Market Cap is $4.01B. At end of 2025 it was $2.49B. Ranked #1419 of 3,116 in US market (top 46%), #487 of 1,472 on NASDAQ (top 33%), #81 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.01B | US#1,419/3,116 Sec#81/265 |
| Revenue | $308M | US#2,419/3,116 Sec#95/265 |
| Net Income | $-64M | US—/3,116 Sec—/265 |
| Total Assets | $641M | US#2,665/3,116 Sec#138/265 |
| Net Assets | $143M | US#2,746/3,116 Sec#206/265 |
| Employees | 624 | US#2,169/3,116 Sec#73/265 |
| Value | ||
| P/B | 28.06x | US#2,850/3,116 Sec#226/265 |
| P/S | 13.02x | US#2,792/3,116 Sec#132/265 |
| FCF Yield | -0.60% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -44.68% | US#2,652/3,116 Sec#149/265 |
| ROA | -9.97% | US#2,653/3,116 Sec#101/265 |
| Op. Margin | -12.16% | US#2,531/3,116 Sec#95/265 |
| Revenue Growth | 50.13% | US#223/3,116 Sec#49/265 |
| Financial Health | ||
| Debt Ratio | 342.87% | US#2,186/3,116 Sec#215/265 |
| Total Debt | $410M | US#1,965/3,116 Sec#69/265 |
| FCF | $-24M | US#2,440/3,116 Sec#98/265 |
| Cash | $170M | US#1,855/3,116 Sec#123/265 |
| Current Ratio | 4.79x | US#492/3,116 Sec#148/265 |
| Performance | ||
| 1Y Return | 44.35% | US#335/3,116 Sec#64/265 |
| 1M Return | -11.60% | US#2,083/3,116 Sec#140/265 |
| From 52W High | -18.48% | US#718/3,116 Sec#42/265 |
| 1Y MDD | -39.35% | US#1,912/3,116 Sec#121/265 |
| Trading | ||
| Volume | 2,281,444 shares | US#801/3,116 Sec#72/265 |
| Trading Value | $59M | US#1,102/3,116 Sec#71/265 |
| Per Share | ||
| EPS | $-0.40 | US—/3,116 Sec—/265 |
| BPS | $0.89 | US#2,708/3,116 Sec#205/265 |
Company Info
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.